VAN WIJMEERSCH, Bart

Email Alert RSS Feed

Profile

Full Name
VAN WIJMEERSCH, Bart
Email
bart.vanwijmeersch@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Refined By:
Author:  Wiendl, H.
Author:  Daizadeh, N.

Results 1-6 of 6 (Search time: 0.002 seconds).

Issue DateTitleContributor(s)TypeCat.
12019Alemtuzumab improves outcomes in RRMS patients who switched from SC IFNB-1a: 6-year follow-up of CARE-MS I Patients (TOPAZ Study)Montalban, X.; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M.; Lycke, J.; Massacesi, L.; Naismith, R. T.; Nakamura, K.; Pandey, K.; Schippling, S.; Vermersch, P.; Wiendl, H.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, BartJournal ContributionM
22018Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extensionVAN WIJMEERSCH, Bart; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; Jacobs, Alessia; Wiendl, H.Journal ContributionM
32018Lack of apparent association between lymphocyte repopulation kinetics and autoimmune events in alemtuzumab-treated patients with relapsing-remitting Multiple Sclerosis through 6 years: CARE-MS extensionWiendl, H.; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; JACOBS, Andre; VAN WIJMEERSCH, BartJournal ContributionM
42018No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosisWiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, BartJournal ContributionM
52018No correlation between lymphocyte pharmacodynamics and autoimmune adverse events following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosisWiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; Jacobs, Alessia; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, BartJournal ContributionM
62018Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study)VAN WIJMEERSCH, Bart; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M. M.; Lycke, J.; Massacesi, L.; Montalban, X.; Naismith, R. T.; Pandey, K.; Schippling, S.; Vermersch, P.; Chung, L.; Daizadeh, N.; Rodriguez, C. E.; Nakamura, K.; Wiendl, H.Journal ContributionM